{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T18:53:53Z","timestamp":1780426433613,"version":"3.54.1"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2004,6]]},"DOI":"10.1007\/s11926-004-0075-3","type":"journal-article","created":{"date-parts":[[2007,6,2]],"date-time":"2007-06-02T15:34:54Z","timestamp":1180798494000},"page":"240-247","source":"Crossref","is-referenced-by-count":60,"title":["Serum uric acid-lowering therapies: Where are we heading in management of hyperuricemia and the potential role of uricase"],"prefix":"10.1007","volume":"6","author":[{"given":"John S.","family":"Bomalaski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike A.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"75_CR1","first-page":"2403","volume":"29","author":"E Arrondee","year":"2002","unstructured":"Arrondee E, Michet CJ, Crowson CS, et al.: Epidemiology of gout: is the incidence rising? J Rheumatol 2002, 29:2403\u20132406.","journal-title":"J Rheumatol"},{"key":"75_CR2","first-page":"66","volume":"116","author":"Q Zeng","year":"2003","unstructured":"Zeng Q, Wang Q, Ren C, et al.: Primary gout in Shantou: a clinical and epidemiological study. Chin Med J 2003, 116:66\u201369.","journal-title":"Chin Med J"},{"key":"75_CR3","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/rheumatology\/keg422","volume":"42","author":"SY Chen","year":"2003","unstructured":"Chen SY, Chen CL, Shen ML, Kamatani N: Trends in the manifestations of gout in Taiwan. Rheumatology 2003, 42:1529\u20131533.","journal-title":"Rheumatology"},{"key":"75_CR4","first-page":"841","volume":"30","author":"CS Liu","year":"2003","unstructured":"Liu CS, Li TC, Lin CC: The epidemiology of hyperuricemia in children of Taiwan aborigines. J Rheumatol 2003, 30:841\u2013845.","journal-title":"J Rheumatol"},{"key":"75_CR5","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/S0041-1345(03)00648-1","volume":"35","author":"LA Bonet","year":"2003","unstructured":"Bonet LA: Predictors of mortality following heart transplantation: Spanish Registry of Heart Transplantation 1984\u20132001. Transplant Proc 2003, 35:1946\u20131950.","journal-title":"Transplant Proc"},{"key":"75_CR6","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0041-1345(03)00642-0","volume":"35","author":"JM Moreno","year":"2003","unstructured":"Moreno JM, Cuervas-Mons V, Rubio E, et al.: Chronic renal dysfunction after liver transplantation in adult patients: prevalence, risk factors, and impact on mortality. Transplant Proc 2003, 35:1907\u20131908.","journal-title":"Transplant Proc"},{"key":"75_CR7","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1161\/01.HYP.0000069700.62727.C5","volume":"41","author":"RJ Johnson","year":"2003","unstructured":"Johnson RJ, Kang DH, Feig D, et al.: Is there a pathogenetic role for uric acid in hypertension and renal disease? Hypertension 2003, 41:1183\u20131190. Review article describing the association of hyperuricemia with hypertension, vascular disease, renal disease, and cardiovascular events.","journal-title":"Hypertension"},{"key":"75_CR8","first-page":"468","volume":"42","author":"F Cardona","year":"2003","unstructured":"Cardona F, Tinahones FJ, Collantes E, et al.: The elevated prevalence of apolipoprotein E2 in patients with gout is associated with reduced renal excretion of urates. Rheumatology 2003, 42:468\u2013472.","journal-title":"Rheumatology"},{"key":"75_CR9","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMcp030733","volume":"349","author":"RA Terkeltaub","year":"2003","unstructured":"Terkeltaub RA: Clinical practice: gout. N Engl J Med 2003, 349:1647\u20131655. Excellent review article on gout using a patient presentation as a springboard for discussion. Includes easy-to-read figures and tables that summarize treatment regimens and considerations in therapy.","journal-title":"N Engl J Med"},{"key":"75_CR10","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1001\/jama.289.21.2857","volume":"289","author":"KT Rott","year":"2003","unstructured":"Rott KT, Agudelo CA: Gout. JAMA 2003, 289:2857\u20132860. Excellent review article on gout emphasizing comorbidities and characteristics of classic versus atypical gout.","journal-title":"JAMA"},{"key":"75_CR11","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s11926-003-0069-6","volume":"5","author":"S Pay","year":"2003","unstructured":"Pay S, Terkeltaub RA: The case for uricase in gout. Curr Rheumatol Rep 2003, 5:213\u2013214. Short article focusing on the potential usefulness of uricase formulated with polyethylene glycol.","journal-title":"Curr Rheumatol Rep"},{"key":"75_CR12","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/oxfordjournals.molbev.a004123","volume":"19","author":"M Oda","year":"2002","unstructured":"Oda M, Satta Y, Takenaka O, Takahata N: Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol Biol Evol 2002, 19:640\u2013653.","journal-title":"Mol Biol Evol"},{"key":"75_CR13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1042\/BA20010083","volume":"36","author":"A Bayol","year":"2002","unstructured":"Bayol A, Capdevvielle J, Malazzi P, et al.: Modification of a reactive cysteine explains differences between rasburicase and uricozyme, a natural Aspergillus flavus uricase. Biotechnol Appl Biochem 2002, 36:21\u201331.","journal-title":"Biotechnol Appl Biochem"},{"key":"75_CR14","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1200\/JCO.2001.19.3.697","volume":"19","author":"C-H Pui","year":"2001","unstructured":"Pui C-H, Mahmoud HM, Wiley JM, et al.: Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 2001, 19:697\u2013704.","journal-title":"J Clin Oncol"},{"key":"75_CR15","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1038\/sj.leu.2402235","volume":"15","author":"C-H Pui","year":"2001","unstructured":"Pui C-H, Jeha S, Irwin D, Camitta B: Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia 2001, 15:1505\u20131509.","journal-title":"Leukemia"},{"key":"75_CR16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1053\/shem.2001.29018","volume":"38","author":"C-H Pui","year":"2001","unstructured":"Pui C-H: Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience. Semin Hematol 2001, 38(suppl):13\u201321.","journal-title":"Semin Hematol"},{"key":"75_CR17","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1182\/blood.V97.10.2998","volume":"97","author":"ST Goldman","year":"2001","unstructured":"Goldman ST, Holcenberg JS, Finklestein JZ, et al.: A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001, 97:2998\u20133003.","journal-title":"Blood"},{"key":"75_CR18","doi-asserted-by":"crossref","first-page":"438","DOI":"10.2165\/00128072-200103060-00005","volume":"3","author":"C-H Pui","year":"2001","unstructured":"Pui C-H: Rasburicase: a viewpoint. Paediatr Drugs 2001, 3:438.","journal-title":"Paediatr Drugs"},{"key":"75_CR19","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2165\/00128072-200103060-00006","volume":"3","author":"S Goldman","year":"2001","unstructured":"Goldman S: Rasburicase: a viewpoint. Paediatr Drugs 2001, 3:439.","journal-title":"Paediatr Drugs"},{"key":"75_CR20","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1373\/49.8.1417","volume":"49","author":"E Lim","year":"2003","unstructured":"Lim E, Bennett P, Beilby J: Sample preparation in patients receiving uric acid oxidase (rasburicase) therapy. Clin Chem 2003, 49:1417\u20131419.","journal-title":"Clin Chem"},{"key":"75_CR21","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/annonc\/mdh029","volume":"5","author":"H Berg van den","year":"2004","unstructured":"van den Berg H, Reintsema AM: Renal tubular damage in rasburicase: risks of alkalinisation. Ann Oncol 2004, 5:175\u2013176.","journal-title":"Ann Oncol"},{"key":"75_CR22","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1517\/14656566.3.4.433","volume":"3","author":"C-H Pui","year":"2002","unstructured":"Pui C-H: Rasburicase: a potent uricolytic agent. Expert Opin Pharmacother 2002, 3:433\u2013442.","journal-title":"Expert Opin Pharmacother"},{"key":"75_CR23","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1093\/ajhp\/60.21.2213","volume":"60","author":"MT Holdsworth","year":"2003","unstructured":"Holdsworth MT, Nguyen P: Role of iv allopurinol and rasburicase in tumor lysis syndrome. Am J Health Syst Pharm 2003, 60:2213\u20132222.","journal-title":"Am J Health Syst Pharm"},{"key":"75_CR24","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1345\/aph.1C336","volume":"37","author":"BT Yim","year":"2003","unstructured":"Yim BT, Sims-McCallum RP, Chong PH: Rasburicase for the treatment and prevention of hyperuricemia. Ann Pharmacother 2003, 37:1047\u20131054.","journal-title":"Ann Pharmacother"},{"key":"75_CR25","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00520-002-0435-3","volume":"11","author":"L Annemans","year":"2003","unstructured":"Annemans L, Moeremans K, Lamotte M, et al.: Pan-European multicenter economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricemia and tumor lysis syndrome in hematological cancer patients. Support Care Cancer 2003, 11:249\u2013257.","journal-title":"Support Care Cancer"},{"key":"75_CR26","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.3816\/CLM.2002.s.012","volume":"3","author":"MS Cairo","year":"2002","unstructured":"Cairo MS: Prevention and treatment of hyperuricemia in hematological malignancies. Clin Lymphoma 2002, 3(suppl):S26-S31.","journal-title":"Clin Lymphoma"},{"key":"75_CR27","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1038\/sj.leu.2403161","volume":"17","author":"M Hummel","year":"2003","unstructured":"Hummel M, Buchheidt D, Reiter S, et al.: Successful treatment of hyperuricemia with low doses of recombinant urate oxidase in four patients with hematologic malignancy and tumor lysis syndrome. Leukemia 2003, 17:2452\u20132544.","journal-title":"Leukemia"},{"key":"75_CR28","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1345\/aph.1D111","volume":"37","author":"AC Lee","year":"2003","unstructured":"Lee AC, Li CH, So KT, Chan R: Treatment of impending tumor lysis with single-dose rasburicase. Ann Pharmacother 2003, 37:1614\u20131617.","journal-title":"Ann Pharmacother"},{"key":"75_CR29","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/sj.leu.2402847","volume":"17","author":"PM Navolanic","year":"2003","unstructured":"Navolanic PM, Pui C-H, Larson RA, et al.: Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002. Leukemia 2003, 17:499\u2013514. A meeting report on the role of rasburicase in tumor lysis hyperuricemia.","journal-title":"Leukemia"},{"key":"75_CR30","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1586\/14737140.3.4.429","volume":"3","author":"S Goldman","year":"2003","unstructured":"Goldman S: Rasburicase: potential role in managing tumor lysis in patients with hematological malignancies. Expert Rev Anticancer Ther 2003, 3:89\u201393.","journal-title":"Expert Rev Anticancer Ther"},{"key":"75_CR31","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3816\/CLM.2003.n.003","volume":"3","author":"RC Ribeiro","year":"2003","unstructured":"Ribeiro RC, Pui C-H: Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies. Clin Lymphoma 2003, 3:225\u2013232.","journal-title":"Clin Lymphoma"},{"key":"75_CR32","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/cncr.11612","volume":"98","author":"A Bosly","year":"2003","unstructured":"Bosly A, Sonet A, Pinkerton CR, et al.: Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer 2003, 98:1048\u20131054.","journal-title":"Cancer"},{"key":"75_CR33","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.1200\/JCO.2003.04.115","volume":"21","author":"B Coiffier","year":"2003","unstructured":"Coiffier B, Mounier N, Bologna S, et al.: Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin\u2019s lymphoma: results of the GRAAL1 (Groupe d\u2019Etude des Lymphomes de l\u2019Adulte Trial) on rasburicase activity in adult lymphoma study. J Clin Oncol 2003, 21:4402\u20134406.","journal-title":"J Clin Oncol"},{"key":"75_CR34","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrd1033","volume":"2","author":"JM Harris","year":"2003","unstructured":"Harris JM, Chess RB: Effect of pegylation on pharmaceuticals. Nature Rev Drug Disc 2003, 2:214\u2013221. Excellent short review on the principles of pegylation and application to biologics.","journal-title":"Nature Rev Drug Disc"},{"key":"75_CR35","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1681\/ASN.V1251001","volume":"12","author":"SJ Kelly","year":"2001","unstructured":"Kelly SJ, Delnomdedieu M, Oliverio MI, et al.: Diabetes insipidus in uricase-deficient mice: a model for evaluating therapy with poly(ethylene glycol)-modified uricase. J Am Soc Nephrol 2001, 12:1001\u20131009.","journal-title":"J Am Soc Nephrol"},{"key":"75_CR36","first-page":"472","volume":"D58","author":"D Vivar\u00e8s","year":"2002","unstructured":"Vivar\u00e8s D, Bonnet\u00e9 F: X-ray scattering studies of Aspergillus flavus urate oxidase: towards a better understanding of PEG effects on the crystallization of large proteins. Acta Cryst 2002, D58:472\u2013479.","journal-title":"Acta Cryst"},{"key":"75_CR37","first-page":"1942","volume":"29","author":"JS Bomalaski","year":"2002","unstructured":"Bomalaski JS, Holtsberg FW, Ensor CM, Clark MA: Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies. J Rheumatol 2002, 29:1942\u20131949. Description of the rationale for choosing C. utilis uricase and polyethylene glycol of 20,000 mw to optimize formulation of the enzyme, and results from preclinical testing.","journal-title":"J Rheumatol"},{"key":"75_CR38","first-page":"S141","volume":"46","author":"JS Bomalaski","year":"2002","unstructured":"Bomalaski JS, Goddard DH, Grezlak D, et al.: Phase I study of uricase formulated with polyethylene glycol (uricase- PEG 20). Arthritis Rheum 2002, 46(suppl):S141.","journal-title":"Arthritis Rheum"},{"key":"75_CR39","first-page":"S535","volume":"48","author":"LH Silveria","year":"2003","unstructured":"Silveria LH, Vargas A, Medina MN: Use of low-dose prednisone in the treatment of the acute gouty attack (AGA). Arthritis Rheum 2003, 48(suppl):S535.","journal-title":"Arthritis Rheum"},{"key":"75_CR40","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2174\/0929867023371229","volume":"9","author":"F Borges","year":"2002","unstructured":"Borges F, Fernandes E, Roleira F: Progress towards the discovery of xanthine oxidase inhibitors. Curr Med Chem 2002, 9:195\u2013217.","journal-title":"Curr Med Chem"},{"key":"75_CR41","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0378-8741(98)00119-6","volume":"64","author":"PL Owen","year":"1999","unstructured":"Owen PL, Johns T: Xanthine oxidase inhibitory activity of northeastern North American plant remedies used for gout. J Ethnopharmacol 1999, 64:149\u2013160.","journal-title":"J Ethnopharmacol"},{"key":"75_CR42","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0378-8741(00)00305-6","volume":"73","author":"LD Kong","year":"2000","unstructured":"Kong LD, Cai Y, Huang WW, et al.: Inhibition of xanthine oxidase by some Chinese medicinal plants used to treat gout. J Ethnopharmacol 2000, 73:199\u2013207.","journal-title":"J Ethnopharmacol"},{"key":"75_CR43","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/14756360290019944","volume":"17","author":"E Fernandes","year":"2002","unstructured":"Fernandes E, Carvalho F, Silva AM, et al.: 2-styrylchromones as novel inhibitors of xanthine oxidase: a structure-activity study. J Enzyme Inhib Med Chem 2002, 17:45\u201348.","journal-title":"J Enzyme Inhib Med Chem"},{"key":"75_CR44","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S0960-894X(01)00093-2","volume":"11","author":"S Isibuchi","year":"2001","unstructured":"Isibuchi S, Morimoto H, Oe T, et al.: Synthesis and structureactivity relationships of 1-phenylpyrazoles as xanthine oxidase inhibitors. Bioorg Med Chem Lett 2001, 11:879\u2013882.","journal-title":"Bioorg Med Chem Lett"},{"key":"75_CR45","first-page":"S530","volume":"48","author":"T Osajima","year":"2003","unstructured":"Osajima T, Kamezawa M, Fukunari A, et al.: Pharmacokinetics and pharmacodynamics of Y-700, a potent and non-renal excretion type of xanthine oxidase inhibitor, in healthy male volunteers. Arthritis Rheum 2003, 48(suppl):S530.","journal-title":"Arthritis Rheum"},{"key":"75_CR46","first-page":"S530","volume":"48","author":"S Noma","year":"2003","unstructured":"Noma S, Verho M, Iwane, et al.: Safety, tolerability, pharmacokinetics, and lowering uric acid effect of repeated daily dosing with Y-700, a novel xanthine oxidase inhibitor, in health male volunteers. Arthritis Rheum 2003, 48(suppl):S530.","journal-title":"Arthritis Rheum"},{"key":"75_CR47","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1074\/jbc.M208307200","volume":"278","author":"K Okamoto","year":"2003","unstructured":"Okamoto K, Eger BT, Nishino T, et al.: An extremely potent inhibitor of xanthine oxidoreductase: crystal structure of the enzyme-inhibitor complex and mechanism of action. J Biol Chem 2003, 278:1848\u20131855.","journal-title":"J Biol Chem"},{"key":"75_CR48","first-page":"S531","volume":"48","author":"L Zhao","year":"2003","unstructured":"Zhao L, Takano Y, Horiuchi H: Effect of febuxostat, a novel non-purine, selective inhibitor of xanthine oxidase (NPSIXO) on enzymes in purine and pyrimidine metabolism pathway. Arthritis Rheum 2003, 48(suppl):S531.","journal-title":"Arthritis Rheum"},{"key":"75_CR49","first-page":"S529","volume":"48","author":"S Swan","year":"2003","unstructured":"Swan S, Khosravan R, Mayer MD, et al.: Effect of renal impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat (TMX-67), a novel non-purine selective inhibitor of xanthine oxidase. Arthritis Rheum 2003, 48(suppl):S529.","journal-title":"Arthritis Rheum"},{"key":"75_CR50","first-page":"S530","volume":"48","author":"N Kamatani","year":"2003","unstructured":"Kamatani N, Fujimori S, Hada T, et al.: Phase II dose-response clinical trial using febuxostat (TMX-67), a novel-type xanthine oxidase\/xanthine dehydrogenase inhibitor, for gout and hyperuricemia. Arthritis Rheum 2003, 48(suppl):S530.","journal-title":"Arthritis Rheum"},{"key":"75_CR51","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/ard.62.6.572","volume":"62","author":"S Takahashi","year":"2003","unstructured":"Takahashi S, Moriwaki Y, Yamamoto T, et al.: Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and\/or losartan on uric acid metabolism. Ann Rheum Dis 2003, 62:572\u2013575.","journal-title":"Ann Rheum Dis"},{"key":"75_CR52","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1136\/ard.60.10.984a","volume":"60","author":"AL Hepburn","year":"2001","unstructured":"Hepburn AL, Kaye SA, Feher MD: Fenofibrate: a new treatment for hyperuricemia and gout? Ann Rheum Dis 2001, 60:984\u2013986.","journal-title":"Ann Rheum Dis"},{"key":"75_CR53","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00005344-199907000-00010","volume":"34","author":"M Elisaf","year":"1999","unstructured":"Elisaf M, Tsimichodimos V, Bairaktari E, et al.: Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia. J Cardiovasc Pharmacol 1999, 34:60\u201363.","journal-title":"J Cardiovasc Pharmacol"},{"key":"75_CR54","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/rheumatology\/keg103","volume":"42","author":"MD Feher","year":"2003","unstructured":"Feher MD, Hepburn AL, Hogarth MB, et al.: Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. Rheumatology 2003, 42:321\u2013325.","journal-title":"Rheumatology"},{"key":"75_CR55","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10067-002-0658-1","volume":"22","author":"AL Hepburn","year":"2003","unstructured":"Hepburn AL, Kaye SA, Feher MD: Long-term remission from gout associated with fenofibrate therapy. Clin Rheumatol 2003, 22:73\u201376.","journal-title":"Clin Rheumatol"},{"key":"75_CR56","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1185\/030079900750119252","volume":"16","author":"HJ Millionis","year":"2000","unstructured":"Millionis HJ, Elisaf MS: Management of hypertension and dyslipidaemia in patients presenting with hyperuricemia: case histories. Curr Med Res Opin 2000, 16:164\u2013170.","journal-title":"Curr Med Res Opin"},{"key":"75_CR57","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1185\/030079902125000273","volume":"18","author":"A Achimastos","year":"2002","unstructured":"Achimastos A, Liberopoulos E, Nikas S, et al.: The effects of the addition of micronised fenofibrate on uric acid metabolism in patients receiving indapamide. Curr Med Res Opin 2002, 18:59\u201363.","journal-title":"Curr Med Res Opin"},{"key":"75_CR58","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1136\/ard.62.6.497","volume":"62","author":"T Bardin","year":"2003","unstructured":"Bardin T: Fenofibrate and losartan. Ann Rheum Dis 2003, 62:497\u2013498.","journal-title":"Ann Rheum Dis"},{"key":"75_CR59","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1291\/hypres.26.509","volume":"26","author":"O Ito","year":"2003","unstructured":"Ito O, Hasegawa Y, Sato K, et al.: A case of exercise-induced acute renal failure in a patient with idiopathic renal hypouricemia developed during antihypertensive therapy with losartan and trichlormethiazide. Hypertension Res 2003, 26:509\u2013513.","journal-title":"Hypertension Res"},{"key":"75_CR60","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1093\/ndt\/gfg341","volume":"18","author":"J Chanard","year":"2003","unstructured":"Chanard J, Toupance O, Lavaud S, et al.: Amlodipine reduces cyclosporin-induced hyperuricaemia in hypertensive renal transplant recipients. Nephrol Dial Transplant 2003, 18:2147\u20132153.","journal-title":"Nephrol Dial Transplant"},{"key":"75_CR61","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1093\/ndt\/18.3.603","volume":"18","author":"F Perez-Ruiz","year":"2003","unstructured":"Perez-Ruiz F, Gomez-Ullate P, Amenabar JJ, et al.: Long-term efficacy of hyperuricaemia treatment in renal transplant patients. Nephrol Dial Transplant 2003, 18:603\u2013606.","journal-title":"Nephrol Dial Transplant"},{"key":"75_CR62","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/jn\/133.6.1826","volume":"133","author":"RA Jacob","year":"2003","unstructured":"Jacob RA, Spinozzi GM, Simon VA, et al.: Consumption of cherries lowers plasma urate in healthy women. J Nutr 2003, 133:1826\u20131829.","journal-title":"J Nutr"},{"key":"75_CR63","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1093\/rheumatology\/keg402","volume":"42","author":"FS Facchini","year":"2003","unstructured":"Facchini FS: Near-iron deficiency-induced remission in gouty arthritis. Rheumatology 2003, 42:1550\u20131555.","journal-title":"Rheumatology"},{"key":"75_CR64","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1093\/rheumatology\/keg305","volume":"42","author":"M Rull","year":"2003","unstructured":"Rull M, Clayburne G, Sieck M, Schumacher HR: Intra-articular corticosteroid preparations: different characteristics and their effect during inflammation induced by monosodium urate crystals in the rat subcutaneous air pouch. Rheumatology 2003, 42:1093\u20131100.","journal-title":"Rheumatology"},{"key":"75_CR65","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/S0149-2918(03)80158-3","volume":"25","author":"KY Kim","year":"2003","unstructured":"Kim KY, Schumacher HR, Hunsche E, et al.: A literature review of the epidemiology and treatment of acute gout. Clin Ther 2003, 25:1593\u20131617. Excellent review of the epidemiology, treatment, and burden of illness for acute gout.","journal-title":"Clin Ther"},{"key":"75_CR66","first-page":"60","volume":"1","author":"BE Anderson","year":"2002","unstructured":"Anderson BE, Adams DR: Allopurinol hypersensitivity syndrome. J Drugs Dermatol 2002, 1:60\u201362.","journal-title":"J Drugs Dermatol"},{"key":"75_CR67","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/00124743-200212000-00015","volume":"8","author":"LA Hoffman","year":"2002","unstructured":"Hoffman LA: My gout and allopurinol desensitization. J Clin Rheumatol 2002, 8:354\u2013357.","journal-title":"J Clin Rheumatol"},{"key":"75_CR68","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.10511","volume":"47","author":"F Perez-Ruiz","year":"2002","unstructured":"Perez-Ruiz F, Calabozo M, Pijoan JI, et al.: Effect of urate lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002, 47:356\u2013360.","journal-title":"Arthritis Rheum"},{"key":"75_CR69","first-page":"S40","volume":"85","author":"P Hanvivadhanakul","year":"2002","unstructured":"Hanvivadhanakul P, Akkasilpa S, Deesomchok U: Efficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients. J Med Assoc Thai 2002, 85(suppl):S40-S47.","journal-title":"J Med Assoc Thai"},{"key":"75_CR70","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.cccn.2003.09.019","volume":"339","author":"Z Tsutsumi","year":"2004","unstructured":"Tsutsumi Z, Moriwaki Y, Takahashi S, et al.: Oxidized lowdensity lipoprotein autoantibodies in patients with primary gout: effect of urate-lowering therapy. Clin Chim Acta 2004, 339:117\u2013122.","journal-title":"Clin Chim Acta"},{"key":"75_CR71","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1046\/j.1440-1746.2002.02692.x","volume":"17","author":"M Arai","year":"2002","unstructured":"Arai M, Yokosuka O, Fujiwara K, et al.: Fulminant hepatic failure associated with benzbromarone treatment: a case report. J Gastoenterol Hepatol 2002, 17:625\u2013626.","journal-title":"J Gastoenterol Hepatol"},{"key":"75_CR72","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1159\/000064077","volume":"92","author":"A Franco","year":"2002","unstructured":"Franco A, Jimenez L, Torralba J, et al.: Acute uric acid nephropathy by overdosage of benziodarone in a renal transplant recipient. Nephron 2002, 92:746\u2013747.","journal-title":"Nephron"},{"key":"75_CR73","first-page":"U109","volume":"115","author":"S Kumar","year":"2002","unstructured":"Kumar S, Gow P: A survey of indications, results and complication of surgery for tophaceous gout. N Z Med J 2002, 115:U109-U112.","journal-title":"N Z Med J"},{"key":"75_CR74","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/01.SAP.0000067723.32532.97","volume":"51","author":"SS Lee","year":"2003","unstructured":"Lee SS, Lin SD, Lai CS, et al.: The soft-tissue shaving procedure for deformity management of chronic tophaceous gout. Ann Plast Surg 2003, 51:372\u2013375.","journal-title":"Ann Plast Surg"},{"key":"75_CR75","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1136\/ard.62.1.90","volume":"62","author":"Y-B Park","year":"2003","unstructured":"Park Y-B, Park Y-S, Lee S-C, et al.: Clinical analysis of gouty patients with normouricaemia at diagnosis. Ann Rheum Dis 2003, 62:90\u201392.","journal-title":"Ann Rheum Dis"},{"key":"75_CR76","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1046\/j.1523-1755.2003.t01-2-00171.x","volume":"64","author":"HJ Kramer","year":"2003","unstructured":"Kramer HJ, Choi HK, Atkinson K, et al.: The association between gout and nephrolithiasis in men: the Health Professionals\u2019 Follow-Up Study. Kidney Int 2003, 64:1022\u20131026.","journal-title":"Kidney Int"},{"key":"75_CR77","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0002-9343(03)00201-8","volume":"115","author":"CY Pak","year":"2003","unstructured":"Pak CY, Poindexter JR, Adams-Huet B, Pearle MS: Predictive value of kidney stone composition in the detection of metabolic abnormalities. Am J Med 2003, 115:26\u201332.","journal-title":"Am J Med"},{"key":"75_CR78","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S1388-9842(02)00086-7","volume":"4","author":"LE Spieker","year":"2002","unstructured":"Spieker LE, Ruschitzka FT, L\u00fcscher TF, et al.: The management of hyperuricemia and gout in patients with heart failure. Eur J Heart Fail 2002, 4:203\u2013410.","journal-title":"Eur J Heart Fail"},{"key":"75_CR79","first-page":"2437","volume":"30","author":"J Darmawan","year":"2003","unstructured":"Darmawan J, Rasker JJ, Nuralim H: The effect of control and self-medication of chronic gout in a developing country: outcome after 10 years. J Rheumatol 2003, 30:2437\u20132443.","journal-title":"J Rheumatol"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-004-0075-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-004-0075-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-004-0075-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T13:59:11Z","timestamp":1628949551000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-004-0075-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":79,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["75"],"URL":"https:\/\/doi.org\/10.1007\/s11926-004-0075-3","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6]]}}}